Description
mesoestetic melan tran3x gel-cream is a treatment gel-cream that gradually helps reduce hyperpigmentation and prevent its reappearance. Suitable for combination skin with hyperpigmentation.
Key ingredients include Tranexamic Acid which treats existing skin discolouration and stubborn dark marks while also preventing reoccurrence at its onset. Niacinamide also known as Vitamin B3, improves elasticity, and pigmentation and enhances skin barrier function. Jojoba Oil is structurally and chemically similar to human skin oil (sebum) helping to balance oil production. Lactic Acid is an Alpha Hydroxy Acid that works by breaking down the ‘glue’ between skin cells, causing them to slough off and reveal the newer, shinier, healthier skin underneath. Salicylic Acid is a Beta Hydroxy Acid that exfoliates, refines pores, and reduces the formation of acne. Kojic Acid is an antioxidant and skin-brightener, it inhibits melanin production and treats age spots, post-inflammatory hyperpigmentation, and melasma. Contains a fragrance.
Instructions for use:
Apply a thin layer all over your skin, after the melan tran3x concentrate has been absorbed.
Can be used both morning and evening.
It is always important to use a high factor, broad spectrum sunscreen daily but even more so when using active ingredients.
Ingredients:
AQUA, ISODECYL NEOPENTANOATE, TRANEXAMIC ACID, NIACINAMIDE, JOJOBA ESTERS, GLYCERIN, ISOSTEARYL ALCOHOL, BUTYLENE GLYCOL, POLYMETHYLSILSESQUIOXANE, SODIUM CITRATE, HELIANTHUS ANNUUS SEED WAX, BUTYLENE GLYCOL COCOATE, CAPRYLIC/CAPRIC TRIGLYCERIDE, ISONONYL ISONONANOATE, POLYACRYLATE CROSSPOLYMER-6, LACTIC ACID, KOJIC ACID, ARGANIA SPINOSA KERNEL OIL, SALICYLIC ACID, AMINOMETHYLPHOSPHONIC ACID, GLYCOGEN, ACETYL GLYCYL BETA-ALANINE, ACACIA DECURRENS FLOWER WAX, POLYGLYCERIN-3, POLYACRYLATE-13, DIMETHICONE, POLYISOBUTENE, ETHYLHEXYLGLYCERIN, SORBITAN ISOSTEARATE, ETHYLCELLULOSE, POLYSORBATE 20, SODIUM HYDROXIDE, CITRIC ACID, SODIUM METABISULFITE, BHT, DISODIUM EDTA, PHENOXYETHANOL, PARFUM.
Reviews
There are no reviews yet.